Fig. 2

LSD1 silencing enhances sensitivity to CFZ in PI-resistant and PI-sensitive MM cell lines. A KMM-1^PIR and B U266^PIR cell lines were transduced with control shRNA (shCTRL) or shRNA targeting LSD1 (shLSD1_D9, shLSD1_D10) and treated with CFZ (20 nM for KMM-1^PIR and 10 nM forU266^PIR) or DMSO. Cell viability was measured by TMRM staining-flow cytometry 72 hpt. C KMM-1, AMO-1, and KMS-28 cell lines were transduced with shCTRL or with indicated shLSD1 following puromycin selection (1.5 µg/ml). Cell viability was measured by TMRM staining-flow cytometry over time. D KMM-1 cell line was transduced with shCTRL or with indicated shLSD1 and treated with CFZ (2.5 nM). Cell viability was measured by TMRM staining-flow cytometry 72 hpt. E Inducible KMS-28 TTA and F inducible AMO-1 TTA cells were transduced with shCTRL or with reported shLSD1 and treated or not with DOX (1 µg/ml) for 120 h and then 72 h with CFZ (2.5 nM for KMS-28 and 1.25 nM for AMO-1). Cell viability was measured by TMRM staining-flow cytometry 72 hpt. Data are the means ± standard deviation (s.d.) of at least three independent experiments. Asterisks denote statistical significance (**P < 0.01; ***P < 0.001). PIR: proteasome inhibitors resistant; hpt: hours post-treatment; TMRM: tetramethylrhodamine; DOX: doxycycline. E Inducible KMS-28 TTA and F inducible AMO-1 TTA were transduced with shCTRL or with reported shLSD1 and treated or not with DOX (1 µg/ml) for 120 h and then 72 h with CFZ (2.5 nM for KMS-28 and 1.25 nM for AMO-1). Cell viability was measured by TMRM staining-flow cytometry 72 hpt